WASHINGTON — Patients with juvenile idiopathic ... solution to include children and adolescents with polyarticular juvenile idiopathic arthritis and acute lymphoblastic leukemia, according ...

A significant number of children with juvenile idiopathic arthritis treated prior ... with oligoarticular arthritis, 46.7% of patients with polyarticular arthritis, and 45.5% of patients with ...

[51] In patients on ETC, inflammatory activity ... A successful treatment of refractory polyarticular JIA with RXM [66] has opened a new opportunity to also treat JIA-related uveitis.

After MTX was approved for the treatment of RA, pediatric rheumatologists soon explored its use in the pediatric population. Several small uncontrolled descriptive studies supported the ...

FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

JYLAMVO is approved for paediatric patients with acute lymphoblastic leukaemia (ALL) and polyarticular juvenile idiopathic arthritis, making it the sole oral liquid methotrexate approved for both ...

to evaluate if intravenous infusion affects signs and symptoms of oligoarticular or polyarticular juvenile idiopathic arthritis (JIA) and improve quality of life in suffering children aged 2 ...